ENGLEWOOD, Colo., June 19, 2019 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio"), today
announced that it closed its previously announced public
offering. Ampio issued 30,000,000 shares of common stock at
an offering price of $0.40 per common
share for aggregate gross proceeds of $12.0
million, before placement agent fees and other offering
expenses.
The Company intends to use the net proceeds from this offering
for the full cost of its AP-013 clinical trial, titled "A
Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy
and Safety of an Intra-Articular Injection of Ampion in Adults with
pain Due to Severe Osteoarthritis of the Knee," pursuant to its
recently announced Special Protocol Assessment and for other
general corporate purposes.
ThinkEquity, a division of Fordham Financial Management, Inc.,
acted as the exclusive placement agent for this transaction.
The shares of common stock in this offering were offered on a
reasonable best efforts, any and all basis pursuant to an effective
shelf registration statement. A prospectus supplement relating to
the offering was filed by the Company with the SEC on June 17, 2019 and is available on the SEC's
website at www.sec.gov. Copies of the final prospectus
supplement and accompanying prospectus may also be obtained from
ThinkEquity, 17 State Street, 22nd Floor, New York, NY 10004 (646) 968-9355, Email:
prospectus@think-equity.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Ampio Pharmaceuticals, Inc.
Ampio
Pharmaceuticals, Inc. is a development stage biopharmaceutical
company primarily focused on the development of Ampion, our product
candidate, to treat prevalent inflammatory conditions for which
there are limited treatment options.
Forward-Looking Statements
Ampio Pharmaceutical's
statements in this press release that are not historical fact, and
that relate to future plans or events, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by
the use of words such as "believe," "expect," "plan," "predict,"
"anticipate," "intends," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion™ and its classification,
as well as those associated with regulatory approvals and other FDA
responses and decisions including the timing thereof, the Special
Protocol Assessment (SPA), the Biological License Application
(BLA), the ability of Ampio to enter into partnering arrangements,
to initiate, conduct and report the results of clinical trials, and
decisions and changes in business conditions and similar events,
all of which are inherently subject to various risks and
uncertainties. The risks and uncertainties involved include those
detailed from time to time in Ampio's filings with the Securities
and Exchange Commission, including without limitation, under
Ampio's Annual Report on Form 10-K, quarterly reports of Form 10-Q,
periodic reports on Form 8-K, and other documents filed with the
Securities and Exchange Commission. Ampio undertakes no obligation
to revise or update these forward-looking statements, whether as a
result of new information, future events, or otherwise.
Company Contact
Phone: (720) 437-6500
info@ampiopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-announces-closing-of-12-million-public-offering-300871477.html
SOURCE Ampio Pharmaceuticals, Inc.